MARKET

CPIX

CPIX

Cumberland Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.250
+0.020
+0.90%
Closed 16:00 05/16 EDT
OPEN
2.350
PREV CLOSE
2.230
HIGH
2.350
LOW
2.225
VOLUME
9.39K
TURNOVER
14.99K
52 WEEK HIGH
7.51
52 WEEK LOW
2.170
MARKET CAP
33.39M
P/E (TTM)
-6.0500
1D
5D
1M
3M
1Y
5Y
Estimating The Intrinsic Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Does the May share price for Cumberland Pharmaceuticals Inc. ( NASDAQ:CPIX ) reflect what it's really worth? Today, we...
Simply Wall St. · 3d ago
Cumberland Pharmaceuticals Non-GAAP EPS of $0.03, revenue of $11.2M
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): Q1 Non-GAAP EPS of $0.03. Revenue of $11.2M (+6.3% Y/Y). Shares +1.95% AH.
Seekingalpha · 6d ago
Cumberland Q1 Adj. EPS $0.03 Down From $0.07 YoY, Sales $11.20M Up From $10.54M YoY
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.03 per share. This is a 57.14 percent decrease over earnings of $0.07 per share from the same period last year. The company reported $11.20 million in sales
Benzinga · 6d ago
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q1 Revenue $11.2M
MT Newswires · 6d ago
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q1 EPS $0.03
MT Newswires · 6d ago
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement With Verity Pharmaceuticals To Expand Support For Sancuso
Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to
Benzinga · 05/09 13:16
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to support Cumberland's new Sancuso® oncology support ...
PR Newswire · 05/09 13:15
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.
PR Newswire · 05/03 20:05
More
No Data
Learn about the latest financial forecast of CPIX. Analyze the recent business situations of Cumberland Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CPIX stock price target is 8.50 with a high estimate of 8.50 and a low estimate of 8.50.
High8.50
Average8.50
Low8.50
Current 2.250
EPS
Actual
Estimate
-0.21-0.14-0.060.01
Q4 2020
Q1 2021
    0
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 36
Institutional Holdings: 3.04M
% Owned: 20.48%
Shares Outstanding: 14.84M
TypeInstitutionsShares
Increased
5
83.20K
New
7
328.84K
Decreased
7
315.56K
Sold Out
4
29.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.21%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Chairman/Chief Executive Officer/Director
A. Kazimi
Chief Financial Officer/Finance Director
John Hamm
Executive Vice President
Leo Pavliv
Senior Vice President/Chief Compliance Officer
James Herman
Independent Director
Gordon Bernard
Independent Director
Joseph Galante
Independent Director
Jonathan Griggs
Independent Director
Joey Jacobs
Independent Director
James Jones
Independent Director
Kenneth Krogulski
Independent Director
Caroline Young
No Data
No Data
About CPIX
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.

Webull offers kinds of Cumberland Pharmaceuticals, Inc. stock information, including NASDAQ:CPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPIX stock methods without spending real money on the virtual paper trading platform.